A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)
Launched by HOFFMANN-LA ROCHE · Sep 22, 2016
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrollment, although they can have received anti-cancer treatment during that time
- Exclusion Criteria:
- • - Not applicable
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ancona, Marche, Italy
Lisboa, , Portugal
Porto, , Portugal
Timisoara, , Romania
Bari, Puglia, Italy
Wien, , Austria
Brescia, Lombardia, Italy
Sant'andrea Delle Fratte (Pg), Umbria, Italy
Aviano (Pn), Friuli Venezia Giulia, Italy
Modena, Emilia Romagna, Italy
Coimbra, , Portugal
Cluj Napoca, , Romania
Graz, , Austria
Graz, , Austria
Wien, , Austria
Latina, Lazio, Italy
Ponderano (Bi), Piemonte, Italy
Alba Iulia, , Romania
Lisboa, , Portugal
Viterbo, Lazio, Italy
Bucuresti, , Romania
Sora, Lazio, Italy
Sofia, , Bulgaria
Camposampiero, Veneto, Italy
Loures, , Portugal
Plovdiv, , Bulgaria
Varna, , Bulgaria
Lucca, Toscana, Italy
Verona, Veneto, Italy
Palermo, Sicilia, Italy
Cona (Fe), Veneto, Italy
Sofia, , Bulgaria
Firenze, Toscana, Italy
Almada, , Portugal
Plovdiv, , Bulgaria
Craiova, , Romania
Ried Innkreis, , Austria
Klagenfurt, , Austria
Leoben, , Austria
Linz, , Austria
Villach, , Austria
Wiener Neustadt, , Austria
Wien, , Austria
Ruse, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
Stara Zagora, , Bulgaria
Vratza, , Bulgaria
Barletta, Puglia, Italy
Catania, Sicilia, Italy
Legnago (Vr), Veneto, Italy
Bucharest, , Romania
Cluj Napoca, , Romania
Modena, Emilia Romagna, Italy
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials